GAA
MTNB icon

Global Assets Advisory’s Matinas BioPharma MTNB Stock Holding History

Global Assets Advisory’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-365
Closed -$14K – 148
2022
Q3 		$14K Buy
+365
New +$14.3K 0.01% 149

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Global Assets Advisory's MTNB Position: Q4 2022 in Review

Global Assets Advisory sold out of Matinas BioPharma (MTNB) in Q4 2022, closing a stake of 365 shares — an estimated $14K sold.

Global Assets Advisory first reported a position in MTNB in Q3 2022 and held it in 1 quarter. The position peaked at $14K in Q3 2022. 57 funds tracked by Wall St. Rank hold MTNB as of Q4 2022.

  • Global Assets Advisory reported no remaining Matinas BioPharma position as of Q4 2022 after selling out during the quarter.
  • Global Assets Advisory sold 365 Matinas BioPharma shares in Q4 2022, an estimated $14K.
  • Global Assets Advisory first reported a position in Matinas BioPharma in Q3 2022 and held it in 1 quarter.
  • Global Assets Advisory's Matinas BioPharma position peaked at $14K in Q3 2022.
  • 57 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2022.

Based on Global Assets Advisory's 13F filing for Q4 2022, filed 31 Jan 2023.